KM
BCRX icon

Kalos Management’s BioCryst Pharmaceuticals BCRX Stock Holding History

Kalos Management’s Portfolio BCRX Stock Details BCRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-23,900
Closed -$256K – 54
2022
Q2 		$256K Buy
23,900
+450
+2% +$4.64K 0.34% 96
2022
Q1 		$381K Sell
23,450
-1,909
-8% -$30.6K 0.26% 90
2021
Q4 		$340K Buy
25,359
+1,659
+7% +$22K 0.09% 208
2021
Q3 		$318K Sell
23,700
-350
-1% -$5.52K 0.09% 211
2021
Q2 		$395K Hold
24,050
– – 0.16% 162
2021
Q1 		$260K Buy
24,050
+250
+1% +$2.58K 0.08% 239
2020
Q4 		$177K Sell
23,800
-1,000
-4% -$5.16K 0.08% 231
2020
Q3 		$89K Buy
24,800
+5,850
+31% +$25.1K 0.04% 219
2020
Q2 		$90K Hold
18,950
– – 0.04% 206
2020
Q1 		$37K Buy
+18,950
New +$52.2K 0.02% 200
2019
Q4 		– Sell
-18,950
Closed -$53K – 205
2019
Q3 		$53K Buy
+18,950
New +$58.9K 0.02% 191
2019
Q2 		– Sell
-27,443
Closed -$223K – 196
2019
Q1 		$223K Sell
27,443
-1,257
-4% -$10.8K 0.14% 129
2018
Q4 		$251K Sell
28,700
-2,800
-9% -$21.8K 0.12% 152
2018
Q3 		$241K Sell
31,500
-1,000
-3% -$6.72K 0.13% 129
2018
Q2 		$156K Hold
32,500
– – 0.07% 183
2018
Q1 		$156K Sell
32,500
-1,000
-3% -$5.14K 0.09% 109
2017
Q4 		$164K Buy
+33,500
New +$162K 0.08% 196

Other funds holding BCRX

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Fisher Asset Management
Fisher Asset Management Camas, Washington $295B AUM 31.6% 1-Year Est. Return
PAMS
Pictet Asset Management (Switzerland) Geneva 73, Switzerland $84.3B AUM 26.5% 1-Year Est. Return
RM
RP Management New York $139M AUM 37.98% 1-Year Est. Return
Victory Capital Management
Victory Capital Management San Antonio, Texas $156B AUM 27.51% 1-Year Est. Return

Kalos Management's BCRX Position: Q3 2022 in Review

Kalos Management sold out of BioCryst Pharmaceuticals (BCRX) in Q3 2022, closing a stake of 23,900 shares — an estimated $256K sold.

Kalos Management first reported a position in BCRX in Q4 2017 and held it in 17 quarters. The position peaked at $395K in Q2 2021. 234 funds tracked by Wall St. Rank hold BCRX as of Q3 2022.

  • Kalos Management reported no remaining BioCryst Pharmaceuticals position as of Q3 2022 after selling out during the quarter.
  • Kalos Management sold 23,900 BioCryst Pharmaceuticals shares in Q3 2022, an estimated $256K.
  • Kalos Management first reported a position in BioCryst Pharmaceuticals in Q4 2017 and held it in 17 quarters.
  • Kalos Management's BioCryst Pharmaceuticals position peaked at $395K in Q2 2021.
  • 234 funds tracked by Wall St. Rank held BioCryst Pharmaceuticals as of Q3 2022.

Based on Kalos Management's 13F filing for Q3 2022, filed 21 Nov 2022.